Introduction
============

During the last decade a wide number of studies have focused on the potential involvement of the endocannabinoid system in a variety of psychiatric and neurological disorders. The putative psychoactive ingredient of *Cannabis sativa* (marijuana plant), Δ^9^-tetrahydrocannabinol (Δ^9^-THC), as well as the endogenous cannabinoids anandamide (arachidonoyl ethanolamide) and 2-arachidonoylglycerol (2-AG) act primarily through cannabinoid CB~1~ and CB~2~ receptors. These cannabinoid receptors are GPCRs mostly coupled to Gi/o proteins ([@B19]). The CB~1~ receptor is mainly distributed in the CNS, particularly in cortex, basal ganglia, hippocampus, and cerebellum ([@B24]; [@B10]) and generally acts presinaptically inhibiting the release of neurotransmitters. CB~2~ receptors are expressed at much lower levels in the CNS compared with CB~1~ receptors (reviewed in [@B1]). As G~i/o~ coupled GPCRs, CB~1~ and CB~2~ receptors inhibit adenylyl cyclase, but moreover, both receptors are able to activate MAPK, inhibit voltage gated Ca^2+^ channels and activate inwardly rectifying K^+^ channels ([@B8]).

The activation of CB~1~ receptor in the brain leads to the modulation of neuronal excitability, which may be in part responsible of the psychoactive effects of exogenous cannabinoids. In this context, a considerable amount of studies have been performed in order to elucidate the effects of cannabinoids (natural or synthetics) in the development of mental alterations, such as addiction, cognitive deficits, anxiety or psychosis. Importantly, different or opposite behavioral effects have been observed after the administration of Δ^9^-THC or synthetic cannabinoid ligands ([@B13]; [@B30]; [@B37]). It has been demonstrated that for most G protein-coupled receptors, distinct agonists can differentially regulate several signaling pathways through the same receptor by a selective activation of different intracellular effectors. This is a mechanism known as functional selectivity or biased agonism. In this way, cannabinoid receptors have been demonstrated to be capable of coupling to different families of G proteins and/or to beta-arrestin when activated by an agonist drug suggesting that different intracellular responses may be activated depending on the ligand ([@B15]; [@B3]). For instance, for the CB~1~ receptor has been reported that, whereas 2-AG and WIN55,212 have little preference for inhibition of cAMP and phosphorylation of ERK1/2, anandamide and CP55940 were biased toward cAMP inhibition ([@B21]). Moreover, in a recent study [@B11] demonstrated that CB~2~ receptor ligands display strong and varied functional selectivity at canonical (inhibition of adenylyl cyclase) and non-canonical (arrestin recruitment) pathways. Moreover, the intracellular signaling activated by a receptor depends on the cellular system where it is expressed, which may vary across different neuronal environments. In this context, it has been demonstrated that opioid and cannabinoid receptors function through the same pool of G proteins when they are co-transfected, whereas in cells endogenously expressing these receptors signaling occurs through distinct pools of G proteins ([@B39]). Thus, this fact should be taken into consideration when interpreting results acquired in artificially transfected cells vs. native biological systems.

To our knowledge, no study has compared G protein signaling by different cannabinoid drugs in native brain tissue. Thus, in the current study, we performed \[^35^S\]GTPγS scintillation proximity assay (SPAs) coupled with the use of specific antibodies against different Gα protein subunits to evaluate the functional selectivity of different cannabinoid ligands by activating CB~1~ and/or CB~2~ cannabinoid receptors in mouse brain cortex.

Materials and Methods {#s1}
=====================

Animal Procedures
-----------------

Adult C57BL/6J (WT), CB~1~ knock-out (CB~1~^-/-^) ([@B26]), CB~2~ knock-out (CB~2~^-/-^) ([@B5]), and CB~1~/CB~2~ double knock-out (CB~1~^-/-^/CB~2~^-/-^) mice were used in this study. Animals (males, aged 7--8 weeks-old) were housed (6--8 animals per cage) in standard cages under controlled conditions of temperature (23 [+]{.ul} 1°C) and photoperiod (light/dark cycle 14 h: 10 h) and free access to standard rodent chow and water.

Animal Welfare and Ethical Statements
-------------------------------------

All experimental procedures using mice were performed in accordance with the European Directive for the Protection of Vertebrate Animals used for experimental and Other Scientific Purposes (European Union Directive \#86/606/EEC) and approved by the Ethics Committees for Animal Welfare of the University of the Basque Country (UPV/EHU) permit number CEBA1882011 and by the Institutional Review Board (INIA), permit number CEEA2012/021.

Rationale for Choice of Cannabinoid Ligands
-------------------------------------------

In the present study, we decided to investigate the effects of three different cannabinoid ligands. Δ^9^-THC was chosen for being the main psychoactive component of marijuana plant and the putative responsible of the development of mental disorders in humans. WIN55212-2, a synthetic cannabinoid structurally different from Δ^9^-THC, is a potent, non-selective CB~1~/CB~2~ receptor agonist that is frequently used in the studies that try to elucidate the effects of *Cannabis* in the brain. Finally, we wanted to study a ligand structurally similar to endogenous cannabinoids, such as the synthetic anandamide analog arachidonyl-2-chloroethylamide (ACEA). O-2050 was chosen as a neutral cannabinoid antagonist. O-2050 has been proved to be a neutral CB~1~ receptor antagonist in several studies ([@B7]; [@B20]; [@B4]; [@B43]), with quite similar affinity for CB~1~ and CB~2~ receptors. Although, there is some data in the literature suggesting its activity as inverse or even partial agonist at CB~1~ receptors in various tissues ([@B25]; [@B43]) in a previous work of our group, we showed that O-2050 has no effect over \[^35^S\]GTPγS binding and behaves as an antagonist blocking WIN55212-2-mediated activation ([@B12]) (**Figure [1](#F1){ref-type="fig"}**).

![**Chemical structure of the different cannabinoid ligands used.** Representative scheme of the chemical structure of the different cannabinoid ligands used in this study (Δ^9^-tetrahydrocannabinol (Δ^9^-THC), WIN55212-2, arachidonyl-2-chloroethylamide (ACEA) and O-2050).](fphar-07-00415-g001){#F1}

Rationale for Choice of G Protein α Subunit Subtypes
----------------------------------------------------

In the present study, we decided to investigate the ability of cannabinoid receptors to activate different G proteins subtype. We chose at least one G protein subtype representative of each main G protein family and mainly focusing in the inhibitory G proteins for being the cannabinoid canonical pathway (**Figure [2](#F2){ref-type="fig"}**).

![**G protein signaling pathways.** Representative scheme of the signaling pathways linked to each G protein evaluated in this study.](fphar-07-00415-g002){#F2}

Mouse Brain Cortex Membrane Homogenates Preparation
---------------------------------------------------

After sacrifice by cervical dislocation, the brains were rapidly removed, cortices dissected and fresh frozen, and stored immediately at -80°C until use. Preparation of membrane enriched fraction (P2 fraction) was performed as previously described ([@B16]) with minor modifications. Mouse brain cortex samples (approximately 200 mg) from seven mice each time were thawed at 4°C and homogenized with a glass/teflon grinder (IKA labortechnik, Satufen, Germany) (10 strokes at maximum speed) in 30 volumes of homogenization buffer (50 mM Tris-HCl (Invitrogen, Barcelona, Spain), 1 mM EGTA (Sigma-Aldrich, St. Louis, MO, USA), 3 mM MgCl~2~ (Sigma-Aldrich, St. Louis, MO, USA) and 1 mM DTT (Invitrogen, Barcelona, Spain); pH 7.4; supplemented with 250 mM sucrose (Panreac Química S.A.U, Barcelona, Spain). The homogenates were centrifuged at 1,100 × *g* for 10 min at 4°C (Sorvall RC-5C centrifuge, SM-24 rotor; FisherScientific, Madrid, Spain). The pellets (P1 fraction) were discarded and the supernatants were then recentrifuged at 40,000 × *g* for 10 min (4°C). The resultant pellets were resuspended in 20 volumes of fresh cold centrifugation buffer (50 mM Tris-HCl, 1 mM EGTA, 3 mM MgCl~2~ and 1 mM DTT; pH 7.4) with a glass stick and recentrifuged at 40,000 × *g* for 10 min (4°C). The obtained pellets were then resuspended in five volumes of centrifugation buffer. Protein content was determined by the method of Bradford with BSA (Sigma-Aldrich^®^, St. Louis, MO, USA) as standard. Linear regression analysis and extrapolation of the data were carried out with GraphPad Prism 5^®^ software (GraphPad Software, Inc., San Diego, CA, USA). Finally, aliquots of 0.5, 1, and 2 mg were then centrifuged at 21,000 × *g* (Eppendorf 5810R centrifuge; Eppendorf, Madrid, Spain) during 15 min at 4°C. The supernatant layer was carefully discarded and the pellets stored at -80°C until assay.

Antibody-Capture \[^35^S\]GTPγS Scintillation Proximity Assay (SPA)
-------------------------------------------------------------------

Specific activation of different subtypes of Gα proteins was determined using a homogeneous protocol of \[^35^S\]GTPγS SPA coupled with the use of specific antibodies essentially as previously described ([@B12]). \[^35^S\]GTPγS binding was performed in 96-well Isoplates (PerkinElmer Life Sciences, Maanstraat, Germany) and in a final volume of 200 ml containing 1 mM EGTA, 3 mM MgCl~2~, 100 mM NaCl, 0.2 mM DTT, 50 mM Tris-HCl at pH 7.4, 0.4 nM \[^35^S\]GTPγS, 15 μg of protein per well, and different concentrations of GDP depending on the Gα subunit subtype tested. At the end of the 2 h incubation period (30°C), 20 μl of Igepal 1% + SDS 0.1% were added to each well, and plates were incubated at 22°C for 30 min with gentle agitation. Specific antibody for the Gα subunit of interest was then added to each well before an additional 90 min RT incubation period (the antibodies and dilutions employed are described in **Table [1](#T1){ref-type="table"}**). Polyvinyltoluene (PVT) SPA beads coated with protein A (PerkinElmer, S.L., Tres Cantos, Madrid, Spain) were then added (0.75 mg of beads per well), and plates were incubated for 3 h at RT with gentle agitation. Finally, plates were centrifuged (5 min at 1000 × *g*), and bound radioactivity was detected on a MicroBeta TriLux scintillation counter (PerkinElmer S.L., Tres Cantos, Madrid, Spain). In order to test their effect on the \[^35^S\]GTPγS binding to the different Gα subunit subtypes, a single submaximal concentration of the drugs (10 μM) Δ^9^-THC, WIN55212-2, ACEA and/or O-2050, was used. This submaximal concentration was chosen as previously reported ([@B12]) in our previous experimental assays in which we established the standard conditions for this assays. This concentration is the one which give us binding values around the Emax for any drug and subunit subtype combination studied (Supplementary Figure [S1](#SM1){ref-type="supplementary-material"}). Non-specific binding was defined as the remaining \[^35^S\]GTPγS binding in the presence of 10 μM unlabelled GTPγS.

###### 

Antibodies, dilutions, and GDP concentrations employed in the \[^35^S\]GTPγS scintillation proximity assays.

  Target      Description                        Commercial firm   Catalog \#   \[GDP\] (μM)   Ab dilution
  ----------- ---------------------------------- ----------------- ------------ -------------- -------------
  Gα~i1~      Mouse monoclonal anti-Gα~i1~       Santa Cruz        sc-56536     100            1:20
  Gα~i2~      Rabbit polyclonal anti-Gα~i2~      Santa Cruz        sc-7276      50             1:20
  Gα~i3~      Rabbit polyclonal anti-Gα~i3~      Santa Cruz        sc-262       200            1:30
  Gα~o~       Mouse monoclonal anti-Gα~o~        BIOMOL            SA-280       50             1:75
  Gα~z~       Rabbit polyclonal anti-Gα~z~       Santa Cruz        sc-388       100            1:20
  Gα~s~       Rabbit polyclonal anti-Gα~s~       Santa Cruz        sc-383       100            1:20
  Gα~q/11~    Rabbit polyclonal anti-Gα~q/11~    Santa Cruz        sc-392       50             1:20
  Gα~12/13~   Rabbit polyclonal anti-Gα~12/13~   Santa Cruz        sc-28588     100            1:20

Western Blot
------------

For Western blot experiments, membrane enriched fraction (P2 fraction) pellets from mouse brain tissue (cortex) were resuspended in TBS, reaching a concentration of 4 mg protein/ml. Commercial Laemmli 2x (95%) and β-mercaptoethanol (5%) (Sigma-Aldrich^®^, St. Louis, MO, USA) were added to each sample, reaching a final protein concentration of 2 mg/ml. Finally, all the samples were heated at 95°C for 5 min in a Thermoblock (Biometra, Goettingen, Germany) and kept at -20°C until assay. Electrophoresis was carried out in SDS polyacrylamide gels, composed of 5% stacking (0.5 M Tris-HCl, pH 6.8, 10% SDS) and 12% resolving (1.5 M Tris-HCl, pH 8.8, 10% SDS) gels, using a miniprotean system (Bio-Rad Laboratories). Equal protein loading in the gel was verified by simultaneous immunodetection of β-actin (mouse monoclonal antibody anti-β-actin, Sigma Biosciences, St. Louis, MO, USA) with the different Gα subunit subtypes. Proteins were then transferred to nitrocellulose membranes (1 h, 0.3 A) using an electrophoretic transfer system (Bio-Rad Laboratories). The non-specific binding sites in the membranes were blocked for 1 h at RT in blocking solution (3% non-fat dry milk, pH = 7.4 in PBS). Membranes were incubated overnight at 4°C in incubation buffer (3% non-fat dry milk + 0.1% Tween-20 in PBS) containing the appropriate dilution of the specific primary anti-Gα subunit antibody. Antibody specificity, as previously described in the literature ([@B14]; [@B42]), was confirmed in our experimental conditions by Western blot (data not shown). Membranes were washed with PBS and incubated for 1 h at RT and constant agitation with the fluorescent conjugated secondary antibodies (Alexa Fluor^®^ 680 and/or IRDye 800 conjugated antibodies) suitable diluted in incubation buffer. Finally, membranes were rewashed with PBS and immunoreactivity was detected and quantified using the Odyssey Infrared Imaging System (LI-COR Biosciences, Lincoln, NE, USA) and Odyssey Software. Broad-Range pre-stained SDS-PAGE molecular weight standard (Bio-Rad Laboratories, Hercules, CA, USA) was used.

Data Analysis and Statistical Procedures
----------------------------------------

Data were analyzed with GraphPad Prism^TM^ 5.01 software. In order to allow better interpretation of the data, specific binding obtained from \[^35^S\]GTPγS SPAs were transformed to percentage of basal binding (binding values observed in the absence of any exogenous drug) obtained for each Gα protein subunit studied. The statistical comparison of the SPA results was carried out by a two-tailed one sample Student's *t*-test with a significance level of *p* \< 0.05. Immunodensity data obtained from Western blotting assays were transformed to percentage of the control, being the control the mean of immunodensities obtained for WT mice. The statistical comparison of the Western blot results was carried out by a one-way ANOVA test, followed by Dunnet's *post hoc* test for multiple comparisons, with a significance level of *p* \< 0.05. All data are expressed as mean ± SEM values.

Materials
---------

\[^35^S\]GTPγS (4625 × 10^10^ Bq/mmol) was purchased from PerkinElmer Life Sciences (Maanstraat, Germany). Tetrahydrocannabinol (Δ^9^-THC) was purchased from THCPharm GmbH (Frankfurt, Germany); WIN55212-2 and GTPγS were purchased from Sigma-Aldrich (St. Louis, MO, USA); Arachidonyl-2-chloroethylamide ACEA and O-2050 were from Tocris Bioscience (Bristol, UK). All other chemical reagents were of analytical quality and were purchased from Merck (Darmstadt, Germany) or Sigma-Aldrich (St. Louis, MO, USA).

Results
=======

Effects of Δ^9^-THC, WIN55212-2, and ACEA on G Protein Activation in Mouse Brain Membranes
------------------------------------------------------------------------------------------

Cannabinoid receptor ligands were used for the characterization of the functional coupling of cannabinoid receptors to the different G protein α subunit subtypes (Gα~i1~, Gα~i2~, Gα~i3~, Gα~o~, Gα~z~, Gα~s~, Gα~q/11~, and Gα~12/13~) in mouse brain tissue. First, we investigated which Gα subunit subtypes were activated by the natural cannabinoid Δ^9^-THC (10 μM) in mouse brain cortex membrane homogenates (**Figure [3A](#F3){ref-type="fig"}**). As expected, we found that Δ^9^-THC was able to significantly activate several classical AC inhibitory subunits, as Gα~i1~ (113 ± 3%), Gα~o~ (110 ± 2%), and Gα~z~ (113 ± 5%), while exerted no effect on Gα~i2~ or Gα~i3~. Δ^9^-THC was also able to activate the Gα~q/11~ subunit (118 ± 5%). However, no changes were observed when we studied AC stimulatory subunit Gα~s~ and the RhoA activator Gα~12/13~ subunit. To further test if these effects of Δ^9^-THC were cannabinoid-receptor mediated, the same assays were carried out in the presence of a putative neutral antagonist of the CB~1~ receptor, O-2050. In all cases, the activation of these G protein subunits was blocked when membranes were co-incubated with the cannabinoid antagonist O-2050. Next, we investigated the effects on G protein subunit activation induced by the synthetic cannabinoid agonist WIN55212-2 (**Figure [3B](#F3){ref-type="fig"}**). We found that WIN55212-2 significantly increased the binding of \[^35^S\]GTPγS to the all the inhibitory subunits Gα~i1~ (129 ± 6%), Gα~i3~ (129 ± 5%), Gα~o~ (120 ± 4%) and Gα~z~ (134 ± 6%), except Gα~i2~. WIN55212-2 was also able to activate the Gα~q/11~ subunit (131 ± 7%), but not the AC stimulatory subunit Gα~s~. Surprisingly, WIN55212-2 was also able to significantly stimulate the RhoA activator Gα~12/13~ (130 ± 4%). In the same way as previously described for Δ^9^-THC, the activation of these G protein subunits by WIN55212-2 was always blocked by the co-incubation with the cannabinoid antagonist O-2050, except for the case of Gα~z~ (106 ± 1%). Finally, we investigated the effect of the synthetic anandamide analog ACEA on G protein subunit activation in mouse brain tissue (**Figure [3C](#F3){ref-type="fig"}**). When evaluating the classical AC inhibitory subunits, we found that ACEA stimulated Gα~i1~ (121 ± 4%), Gα~i3~ (120 ± 5%), and Gα~o~ (116 ± 4%). However, as occurred with Δ^9^-THC and WIN55212-2, no stimulation was observed in Gα~i2~, suggesting that none of the cannabinoids evaluated exert their effects through Gα~i2~ signaling. Moreover, ACEA had no effect on Gα~z~. As previously observed for the other two cannabinoid ligands evaluated, ACEA also activated Gα~q/11~ subunit (122 ± 7%) while had no effect on Gα~s~. Thus, it seems that none of these cannabinoid ligands are able to activate this AC stimulatory subunit either. No changes were observed when we studied the effects of ACEA on the RhoA activator Gα~12/13~ subunit. Again, the activation of these G protein subunits was blocked when membranes were co-incubated with the cannabinoid antagonist O-2050.

![**Effects of THC, WIN55212-2, and ACEA on G protein activation in mouse brain membranes.** \[^35^S\]GTPγS scintillation proximity assays coupled to immunoprecipitation with specific antibodies against different Gα subunits (Gα~i1~, Gα~i2~, Gα~i3~, Gα~o~, Gα~z~, Gα~s~, Gα~q/11~, and Gα~12/13~) in mouse brain cortical membranes co-incubated with **(A)** THC (10 μM) **(B)** WIN55212-2 (10 μM), or **(C)** ACEA (10 μM) in the presence or absence of the antagonist O-2050 (10 μM). Data are shown as percentage of \[^35^S\]GTPγS basal binding values obtained for each specific subunit. Bars represent mean ± SEM of four to six different experiments carried out in triplicate. Asterisks highlight those normalized values of stimulation or inhibition of basal binding which are statistically different from 100% (Student's *t*-test; ^∗^*p* \< 0.05).](fphar-07-00415-g003){#F3}

Effects of the Cannabinoid Antagonist O-2050 on G Protein Activation in Mouse Brain Membrane Homogenates
--------------------------------------------------------------------------------------------------------

O-2050 was initially synthesized and described as a neutral CB~1~ receptor antagonist, however, there are some evidences suggesting that is able to act as an inverse agonist or even as a partial agonist ([@B43]). For this reason, and in order to validate O-2050 as a useful pharmacological tool to antagonize the effect mediated by cannabinoid receptors, \[^35^S\]GTPγS SPAs were performed in mouse cortical membranes in the presence of O-2050 (10 μM) alone. Under these experimental conditions, neither stimulation nor inhibition of \[^35^S\]GTPγS basal binding values were observed for any of the Gα subunit subtypes studied, with the exception of Gα~z~ (119 ± 1%) (**Figure [4](#F4){ref-type="fig"}**).

![**Effects of the cannabinoid antagonist O-2050 on G protein activation in mouse brain membranes.** \[^35^S\]GTPγS scintillation proximity assays coupled to immunoprecipitation with anti-Gα~i1~, Gα~i3~, Gα~o~, Gα~z~, Gα~q/11~, and Gα~12/13~ specific antibodies in mouse brain cortical membranes co-incubated with the cannabinoid antagonist O-2050 (10 μM). Data are shown as percentage of \[^35^S\]GTPγS basal binding values obtained for each specific subunit. Bars represent mean ± SEM of four to six different experiments carried out in triplicate. Asterisks highlight those normalized values of stimulation or inhibition of basal binding which are statistically different from 100% (Student's *t*-test; ^∗^*p* \< 0.05).](fphar-07-00415-g004){#F4}

Effects of Δ^9^-THC, WIN55212-2, and ACEA on G Protein Activation in Cannabinoid Receptors Knockout Mice
--------------------------------------------------------------------------------------------------------

To further elucidate the role of each cannabinoid receptor subtype in the agonist-mediated activation of the different Gα subunit subtypes, \[^35^S\]GTPγS SPA was performed in brain tissue of CB~1~^-/-^, CB~2~^-/-^, and CB~1~^-/-^/CB~2~^-/-^ mice. For that purpose, brain membranes were incubated with the different cannabinoid ligands (THC, WIN55212-2, or ACEA) and with the specific antibodies against that Gα for which an stimulation with these agonists was observed in WT. **Figure [5A](#F5){ref-type="fig"}** shows the stimulation of the different Gα subunits when brain membranes of the four genotypes were incubated with Δ^9^-THC. The significant stimulation of the inhibitory Gα~i1~ subunit observed in the WT mice was completely absent in the CB~1~^-/-^ and in the CB~1~/CB~2~ double ko mice, but was still present in the CB~2~^-/-^ (108 ± 2%), which suggests that the Δ^9^-THC-mediated stimulation of Gα~i1~ is induced by the activation of CB~1~ receptor. On the other hand, opposite results were obtained for Gα~io~ and Gα~z~, the other two inhibitory subunits that were stimulated by Δ^9^-THC. As previously described, there was a significant Δ^9^-THC-induced stimulation of Gα~o~ and Gα~z~ subunits in the WT. This stimulation was also observed in the CB~1~^-/-^ (115 ± 4% for Gα~o~ and 120 ± 4% for Gα~z~) but not in the CB~2~^-/-^ or the CB~1~^-/-^/CB~2~^-/-^ mice. These data may indicate that, in mouse brain cortical membranes, Δ^9^-THC acts through the CB~2~ receptor to stimulate these inhibitory Gα~o~ and Gα~z~ subunits. Finally, the Δ^9^-THC-induced activation of the Gα~q/11~ subunit observed in the WT mice was not found in the CB~1~^-/-^ and CB~1~^-/-^/CB~2~^-/-^ mice, while remained unchanged in the CB~2~^-/-^ (116 ± 2%). This result indicates that Δ^9^-THC stimulates the Gα~q/11~ subunit acting mainly through the CB~1~ receptor.

![**Effects of THC, WIN55, 212-2, and ACEA on G protein activation in cannabinoid receptors knockout mice.** \[^35^S\]GTPγS scintillation proximity assays coupled to immunoprecipitation with specific antibodies against different Gα subunits in mouse brain cortical membranes of WT, CB~1~ knockout (CB~1~^-/-^), CB~2~ knockout (CB~2~^-/-^) and double CB~1~ and CB~2~ knockout (CB~1~^-/-^/CB~2~^-/-^/double KO) co-incubated with **(A)** THC (10 μM) **(B)** WIN55212-2 (10 μM), or **(C)** ACEA (10 μM). Data are shown as percentage of \[^35^S\]GTPγS basal binding values obtained for each specific subunit. Bars represent mean ± SEM of four to six different experiments carried out in triplicate. Asterisks highlight those normalized values of stimulation or inhibition of basal binding which are statistically different from 100% (Student's *t*-test; ^∗^*p* \< 0.05).](fphar-07-00415-g005){#F5}

**Figure [5B](#F5){ref-type="fig"}** shows the stimulation of different Gα subunits when brain membranes of the four genotypes were incubated with the synthetic cannabinoid agonist WIN55212-2. The significant stimulation of the inhibitory Gα~i1~ and Gα~i3~ subunits induced by WIN55212-2 in the WT mice was not found in the CB~1~^-/-^ nor in the CB~1~^-/-^/CB~2~^-/-^ mice, but was still present in the CB~2~^-/-^ (124 ± 5% for Gα~i1~ and 123 ± 5% for Gα~i3~). On the contrary, the inhibitory subunits Gα~o~ and Gα~z~, which were significantly stimulated in the WT mice, remained stimulated in the CB~1~^-/-^ (111 ± 2% for Gα~o~ and 123 ± 7% for Gα~z~) but not stimulation was found in the CB~2~^-/-^ nor in the CB~1~^-/-^/CB~2~^-/-^ mice. These results suggest that the inhibitory signaling of WIN55212-2 in the mice brain through Gα~i1~ and Gα~i3~ activation seems to be mediated by the CB~1~ receptor, while the stimulation of Gα~o~ and Gα~z~ would be mediated by the CB~2~ receptor activation. The significant activation of the Gα~q/11~ subunit induced by WIN55212-2 in the WT mice was completely absent in the CB~1~^-/-^ mice, as well as in the CB~1~/CB~2~ double ko mice. On the contrary, a significant stimulation of Gα~q/11~ subunit (120 ± 5%) was observed in the CB~2~^-/-^ membranes, suggesting that this stimulation is mediated by the CB~1~ receptor. Strikingly, the observed stimulation of the RhoA activator subunit Gα~12/13~ by WIN55212-2 in the WT disappeared in the absence of CB~2~ receptor (both in CB~2~^-/-^ and CB~1~^-/-^/CB~2~^-/-^ mice) suggesting an important role of this CB~2~ receptor in the intracellular signaling through Gα~12/13~ in the brain.

Finally, the same experiments were performed incubating the brain membranes with the synthetic anandamide analog ACEA (**Figure [5C](#F5){ref-type="fig"}**). Surprisingly, the significant stimulation of Gα~i1~ that was observed in the WT mice was still found in all the genotypes evaluated. These results suggest that the inhibitory effect of ACEA mediated by the Gα~i1~ subunit activation may be independent of cannabinoid receptors. On the other hand, the significant stimulation of Gα~i3~ subunit induced by ACEA was not observed in brain membranes of CB~1~^-/-^ mice but was still significant in CB~2~^-/-^ membranes (111 ± 3%). No stimulation was observed in the CB~1~^-/-^/CB~2~^-/-^ mice. Regarding the Gα~o~ subunit, there was a significant stimulation in the absence of CB~1~ receptors (115 ± 1%), while this stimulation was not observed in the brain membranes of CB~2~^-/-^ mice, suggesting the necessary role of this receptor in the activation of Gα~o~ induced by the agonist ACEA. The activation of the Gα~q/11~ subunit was observed in both CB~1~^-/-^ (117 ± 2%) and CB~2~^-/-^ (118 ± 4%) but not in the CB~1~^-/-^/CB~2~^-/-^ mice. Thus, as for Δ^9^-THC and WIN55212-2, the activation of Gα~i3~ and Gα~o~ subunits was mediated by their interaction with CB~1~ and CB~2~ receptors, respectively. However, the stimulation of \[^35^S\]GTPγS binding to Gα~q/11~ subunit seems to be triggered by the activation of both CB~1~ and CB~2~ cannabinoid receptors.

Expression of G Protein Subunits in Knockout Mice for Cannabinoid Receptors
---------------------------------------------------------------------------

In order to determine if a physiological adaptation of knockout mice to the genetic manipulation to inactivate CB~1~ and/or CB~2~ receptors may influence our results by the alteration of the expression level of the different Gα protein subunits, Western blotting assays were carried out in brain cortex membranes of WT, CB~1~^-/-^, CB~2~^-/-^, and CB~1~^-/-^/CB~2~^-/-^ mice.

In the case of Gα~i1~ (**Figure [6A](#F6){ref-type="fig"}**), no changes were observed for CB~1~^-/-^ and CB~2~^-/-^, but a significant reduction (33 ± 10% from WT) of immunodensity was detected in CB~1~^-/-^/CB~2~^-/-^ mice brain membrane homogenates. No significant differences were found in the expression of Gα~o~ (**Figure [6C](#F6){ref-type="fig"}**) or Gα~12/13~ (**Figure [6F](#F6){ref-type="fig"}**) subunits between the WT, CB~1~^-/-^, CB~2~^-/-^, and CB~1~^-/-^/CB~2~^-/-^ mice brain membranes. However, an increase in the expression of Gα~i3~ (**Figure [6B](#F6){ref-type="fig"}**) in both CB~2~^-/-^ (139 ± 7%) and CB~1~^-/-^/CB~2~^-/-^ mice (140 ± 7%) was found when compared to the WT and CB~1~^-/-^ animals. On the contrary, Gα~z~ immunodensity was significantly increased in the CB~1~^-/-^ mice (129 ± 4%) while no changes were found in the rest of the genotypes when comparing to the WT (**Figure [6D](#F6){ref-type="fig"}**). Finally, the expression of Gα~q/11~ (**Figure [6E](#F6){ref-type="fig"}**) was significantly increased in brain membranes of CB~2~^-/-^ mice (137 ± 7%) but not in WT, CB~1~^-/-^ and CB~1~^-/-^/CB~2~^-/-^ mice.

![**Expression of G protein subunits in cannabinoid receptors knockout mice.** Immunoreactive signal and representative images obtained by Western blotting with specific antibodies against different Gα subunits: **(A)** Gα~i1~, **(B)** Gα~i3~, **(C)** Gα~o~, **(D)** Gα~z~, **(E)** Gα~q/11~, and **(F)** Gα~12/13~ in mouse brain cortical membranes of WT, CB~1~ knockout (CB~1~^-/-^), CB~2~ knockout (CB~2~^-/-^) and double CB~1~ and CB~2~ knockout (CB~1~^-/-^/CB~2~^-/-^/double KO). Immunoreactivity for β-actin was simultaneously detected on every gel and used as loading control. Normalized values (percentage over controls) of Gα subunits are shown as mean ± SEM of two different experiments carried out in duplicate. Asterisks highlight those values which are statistically different from WT (One-way ANOVA followed by Dunnet's *post hoc* test; ^∗^*p* \< 0.05).](fphar-07-00415-g006){#F6}

Discussion
==========

During the last years, a considerable effort has been made to study the effects of cannabinoids in the brain trying to elucidate the mechanisms by which these compounds may facilitate mental disorders, such as addiction, cognitive deficits, anxiety or psychosis. In this context, these studies have been performed with different cannabinoid ligands (natural or synthetics), in cells or in native tissue and/or in different animal species (mouse, rat, human...).

There is wide evidence supporting the idea that for most of GPCRs, distinct drugs are able to regulate different signaling pathways by the selective activation of different intracellular effectors. The pharmacological relevance of this fact is that the biological responses not only depend on targeting a specific GPCR but also on the particular pathway that this receptor activates. Different studies have focused on the evaluation of the functional selectivity of cannabinoid receptors, but most of them have been performed in transfected cells expressing the CB~1~ receptor ([@B15]; [@B3]). Moreover, much of these studies explore the signaling pathways activated by different agonists by the evaluation of cAMP production or the phoshorylation of intracellular mediators such as ERK or AKT, with no data about the Gα subtype responsible of these downstream effects. These changes on cAMP concentration or ERK/AKT phosphorylation could be the consequence of the activation of different Gα subtypes, Gβγ dimmers, etc. On the other hand, and interestingly, opposite behavioral effects have been observed after the administration of Δ^9^-THC or synthetic cannabinoid ligands ([@B13]; [@B30]; [@B37]). For example, when evaluating the cannabinoid effects on brain-stimulation reward, [@B13] showed that the potent non-selective CB~1~/CB~2~ receptor agonists WIN55,212-2 and CP 55,940, but not Δ^9^-THC, effectively restored heroin-seeking behavior. In addition, it has been suggested that the signaling of CB~1~ receptors may differ between humans and rodents ([@B41]).

All these frequently contradictory data highlight the relevance of studying, simultaneously, the effects of different cannabinoid ligands in the same tissue and under the same experimental conditions.

For that reason the goal of the present study was to compare the pattern of G protein subunit stimulation triggered by three structurally different cannabinoids, Δ^9^-THC, WIN55212-2 and ACEA in mouse brain cortex. To our knowledge, this is the first study evaluating the cannabinoid-induced stimulation of the different Gα subunits in mouse brain tissue.

WIN55212-2, a synthetic cannabinoid structurally different from Δ^9^-THC, is a potent, non-selective CB~1~/CB~2~ receptor agonist that has been used in many studies of cannabinoid receptor function ([@B31]). The synthetic anandamide analog ACEA is a highly selective agonist for the CB~1~ receptor with a low affinity for CB~2~ receptors ([@B17]).

This study demonstrates that each ligand displays functional selectivity acting as biased agonist for a subset of different G protein subunits. It represents the first characterization of the activation of individual Gα subunits by endogenous cannabinoid receptors in brain cortex. Firstly, we demonstrated that phytocannabinoid Δ^9^-THC differs from the synthetic agonists WIN55212-2 and ACEA in its ability to stimulate Gα~i/o~ protein subunits in brain cortex.

The Gα~i~ subfamily members Gα~i1~, Gα~i2~, and Gα~i3~ were originally identified by their ability to inhibit AC activity ([@B32]; [@B6]; [@B29]). Our results show that Δ^9^-THC, WIN55212-2, and ACEA significantly stimulate Gα~i1~ subunit. Moreover, data from knockout mice suggest that this effect may be CB~1~-mediated in the case of Δ^9^-THC and WIN55 212-2. However, the Gα~i1~ stimulation is still significant in membranes of all genotypes incubated with ACEA, suggesting that this is a non-CB~1~ non-CB~2~ dependant effect and supporting putative actions of ACEA over other receptors ([@B31]). Gα~i3~ subunit was also stimulated in the presence of WIN55212-2 and ACEA, but not of Δ^9^-THC. This stimulation seems to be mediated by CB~1~ receptors as is blocked in the presence of O-2050 and absent in CB~1~^-/-^ or CB~1~^-/-^/CB~2~^-/-^ mice. In the case of Gα~i2~, it has been previously described that WIN55212-2 is able to activate this subunit in rat ([@B33]) and in human brain cortical membranes ([@B12]). However, none of the agonists in the present study stimulated the Gα~i2~ subunit. This discrepancy may be due to inter-specie and/or regional differences, suggesting that WIN55212-2 may signal through different G protein pools in human and mouse brain cortex.

These three Gα~i~ subunits form the Gα~i/o~ subfamily with the neuronal α-subunit Gα~o~, which corresponds to the most abundant Gα protein in brain ([@B40]). In our experimental approach, and in accordance with other studies ([@B15]; [@B34]), Δ^9^-THC, WIN55212-2 and ACEA significantly stimulated Gα~o~. Results obtained in knockout animals show that the stimulation of Gα~o~ in mouse cortex is mediated, at least in part, by CB~2~ receptors, suggesting a necessary role of this receptor in the cannabinoid-induced activation of Gα~o~.

The Gα~z~ subtype is the most divergent member of the inhibitory subfamily and is distributed primarily in neuronal and neuroendocrine cells ([@B18]). While Δ^9^-THC and WIN55212-2, similarly, stimulated Gα~z~, no stimulation of this subunit was observed when membranes were incubated with ACEA, suggesting that ACEA may not signal through this subunit. Additionally, results obtained with knockout mice suggest that the stimulation of Gα~z~ by Δ^9^-THC and WIN55212-2 may be induced by a CB~2~-mediated mechanism.

Unlike Gα~z~, the Gα~s~ family is ubiquitously expressed and couples receptors to AC in a stimulatory fashion ([@B28]). Under the present assay conditions, nor Δ^9^-THC, WIN55212-2 or ACEA were able to activate this stimulatory subunit. Thus, there is no evidence of Gα~s~ coupling of cannabinoid receptors in the presence of any of these drugs in brain tissue. There are contradictory results about the ability of cannabinoid drugs to activate Gα~s~ proteins. In this way, there are data from both CHO cell lines ([@B35]; [@B2]) and HEK cells ([@B34]) expressing CB~1~ receptor, showing the absence of effect as well as a modest but significant coupling of CB~1~ to Gα~s~ triggered by different cannabinoids. It has been proposed that ACEA may elevate cAMP through a non-CB~1~ mechanism, since there is an increase in cAMP in both cells transfected and non-transfected with CB~1~ and pretreated with pertussis toxin ([@B34]). It is important to point out that all these studies have been performed in cell lines. Moreover, they use the accumulation of cAMP in the presence of the Gα~i/o~ inhibitor pertussis toxin as an indirect evaluation of potential coupling of CB~1~ receptors to Gα~s~. This increase in cAMP production can be mediated by a mechanism different from Gα~s~ activation, as they did not explore directly the activation of this subunit. Therefore, the possible increase in cAMP induced by other actors different from Gα~s~ subunits could not be discarded.

The Gα~q/11~ proteins, widely expressed through the CNS, mediate PLC activation, leading to the activation of downstream calcium signaling pathways including PKC and MAPKs activation ([@B38]). In this study, a significant stimulation of Gα~q/11~ was observed in the presence of the three cannabinoids evaluated. It has been previously reported that WIN55212-2 induces the coupling of CB~1~ to Gα~q/11~ in different cellular types ([@B23]; [@B27]). Our results show that not only WIN55212-2 but also Δ^9^-THC and ACEA can activate Gα~q/11~ subunit in mouse brain. Moreover, the activation of this subunit induced by Δ^9^-THC and WIN55212-2 seem to be mediated by the CB~1~ receptor, as demonstrate the data obtained with knockout animals. In the case of ACEA, our data suggest that ACEA modulate Gα~q/11~ through both CB~1~ and CB~2~ cannabinoid receptors.

The Gα~12/13~ proteins regulate important signaling events by the activation of the small GTPase protein RhoA, involved in the regulation of the actin cytoskeleton and cell motility ([@B22]; [@B44]). Under our experimental conditions, a significant stimulation of Gα~12/13~ subunit was observed when membranes were incubated with WIN55212-2 but not with Δ^9^-THC or ACEA. To our knowledge, this is the first study reporting that WIN55212-2 signals through Gα~12/13~ in brain cortex. These data are concordant with other studies suggesting that cannabinoids induce the stimulation of this RhoA-activator ([@B9]; [@B36]). Moreover, our results from knockout mice show that the WIN55212-2-induced signaling through Gα~12/13~ in the brain seems to be mediated, mainly, by the CB~2~ receptor.

Although O-2050 had been described as a CB~1~ antagonist, it displays a complex pharmacological profile. In this context, its good affinity for CB~2~ receptors complicates its use as a tool to evaluate the unique contribution of CB~1~ receptor ([@B43]). We observed that, when alone, O-2050 activated the Gα~z~ subunit. Therefore, in co-incubations, O-2050 behaved always as an antagonist of the effects of Δ^9^-THC, WIN55212-2 and ACEA over all the studied Gα subunit subtypes, except for the Gα~z~ subunit. When WIN55212-2 and O-2050 were co-incubated, the stimulation of Gα~z~ was lower but still significant. In this way, the blockade exerted by O-2050 pharmacologically confirmed the involvement of cannabinoid receptors in the observed stimulations.

Studies in knockout mice provide very valuable data in basic research but in addition to the absence of the targeted protein, we cannot discard the appearance of putative neurodevelopmental compensatory mechanisms. In this work, we have used CB~1~ and/or CB~2~ receptor knockout mice to elucidate the role of each receptor in the observed effects of different ligands on the stimulation of Gα subunits. Moreover, Western blotting assays were carried out in order to unmask the role of a possible adaptation of cannabinoid receptors knockout mice affecting the expression level of the different Gα subtypes on the different genotypes. The observed stimulations in knockout mice may not be influenced by putative neurodevelopmental compensatory mechanisms involving G proteins density. In this way, although expression of some Gα subunits in knockout mice is different from the WT, these changes do not explain the absence of stimulation in CB~1~ or CB~2~ knockout mice. The convergence of our pharmacological and genetic data demonstrate that the results obtained herein with the cannabinoid receptors knockout mice are likely due to the absence of the CB~1~ and/or CB~2~ receptors and not to non-specific changes due to neurodevelopmental adaptations.

Conclusion
==========

Our results demonstrate that, in mouse brain native tissue and under our experimental conditions different exogenous cannabinoids are able to selectively activate different inhibitory and non-inhibitory Gα protein subtypes, through the activation of CB~1~ and/or CB~2~ receptors. However, it is important to be aware of potential limitations. It has been suggested that the signaling of CB~1~ receptors is significantly diminished in humans compared to that of rodents, a finding that may have implications for the use of rodent models for studies of CB~1~ receptor function related to human disease and therapy ([@B41]).

Results of the present study may help to dissect the specific signaling pathways involved in the different pharmacological actions of cannabinoids. Moreover, the knowledge of the specific molecular target responsible of these different physiological effects will help in the design of new biased cannabinoid drugs with more specific therapeutic effect and a reduced range of adverse effects.
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2-AG

:   2- arachidonoylglycerol

ACEA

:   arachidonyl-2-chloroethylamide

CB~1~^-/-^

:   CB~1~ knock-out mice

CB~2~^-/-^

:   CB~2~ knock-out mice

CB~1~^-/-^/CB~2~^-/-^

:   CB~1~ and CB~2~ double knock-out mice

P1

:   pellet fraction

P2

:   membrane enriched fraction

PVT

:   polyvinyltoluene

RT

:   room temperature

SDS

:   sodium dodecyl sulfate

SPA

:   scintillation proximity assay

TBS

:   tris-buffered saline

WT

:   wild type

Δ^9^-THC

:   Δ^9^-tetrahydrocannabinol
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